Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- hemodynamic stability during rapid sequence intubation
研究概览
简要总结
This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension
详细描述
Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life.
Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.
研究设计
- 研究类型
- Interventional
- 干预模型
- Sequential
- 主要目的
- Supportive Care
- 盲法
- None
盲法说明
Participant will receive propofol before induction
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Indication of anesthesia induction
排除标准
- •Protocol violation
- •Monitoring problems
研究组 & 干预措施
Single Arm
Patients will receive bolus dose of remifentanil before intubation
干预措施: Remifentanil (Drug)
结局指标
主要结局
hemodynamic stability during rapid sequence intubation
时间窗: from anesthesia induction up to 5 minutes
no bradycardia and no hypotension
次要结局
未报告次要终点
研究者
Gabriel Magalhaes Nunes Guimaraes
Head of Anesthesia department
Brasilia University Hospital
